Search results
Exeliom to focus on gastric cancer landscape with immune modulating drug
Clinical Trials Arena via Yahoo Finance· 1 day agoPatients in the control arm will receive FOLFOX chemotherapy andOpdivo. The primary endpoint is the...
Bristol Myers Squibb Swings To Quarterly Loss, After String Of Multi-Billion Acquisitions
Benzinga via Yahoo Finance· 2 days agoGrowth Portfolio worldwide revenues increased to $4.8 billion, up 8% or 11% when adjusted for...
Bristol Myers to cut 6% of workforce, trim drug pipeline
BioPharma Dive via Yahoo Finance· 2 days agoIts third highest-grossing product, the multiple myeloma treatment Revlimid, already faces limited...
Bristol Myers Squibb (BMY) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 2 days agoToday, we are seeing the inventory patterns for Opdivo and Camzyos normalizing. And for Sotyktu,...
Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know
Zacks via Yahoo Finance· 5 days agoIncreased sales of the key immuno-oncology drug Opdivo on consistent label expansions for newer...
Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat
Zacks via Yahoo Finance· 2 days agoBristol-Myers' (BMY) first-quarter 2024 loss is narrower than estimated. Sales surpass the consensus...
Reviva Pharmaceuticals (NASDAQ:RVPH) vs. Bristol-Myers Squibb (NYSE:BMY) Head to Head Survey
ETF DAILY NEWS· 3 days agoBristol-Myers Squibb (NYSE:BMY – Get Free Report) and Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) are both medical companies, but which is the better investment? We will compare the ...
Bristol-Myers Squibb (NYSE:BMY) Releases Earnings Results, Beats Expectations By $0.13 EPS
ETF DAILY NEWS· 1 day agoBristol-Myers Squibb (NYSE:BMY – Get Free Report) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($4.40) EPS for the quarter, beating the consensus ...
Bristol-Myers Squibb (NYSE:BMY) Stock Price Up 0.4% on Analyst Upgrade
ETF DAILY NEWS· 7 days agoBristol-Myers Squibb (NYSE:BMY – Get Free Report) shares shot up 0.4% during trading on Friday after Wells Fargo & Company raised their price target on the stock from $51.00 to $52.00. Wells ...
Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by J.W. Cole Advisors Inc.
ETF DAILY NEWS· 6 days agoJ.W. Cole Advisors Inc. boosted its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 9.5% in the 4th quarter, Holdings Channel reports. The firm owned 31,831 shares of the biopharmaceutical ...